Magnet.me - Het slimme netwerk waar studenten en professionals hun stage of baan vinden.
Het slimme netwerk waar studenten en professionals hun stage of baan vinden.
Je carrière begint op Magnet.me
Maak een profiel aan en ontvang slimme aanbevelingen op basis van je gelikete vacatures.
The PhD student will participate in research which is part of the Netherlands Research Council (NWO)-funded consortium RecovAir: REpairing lung damage via reCOVery of stromal heAlth to restore respIRatory function that aims to develop a locally administered regenerative cell therapy for tissue restoration in chronic obstructive pulmonary disease (COPD). This is a prevalent inflammatory disease characterized by irreversible airflow obstruction. The disease has high morbidity and mortality, being the third leading cause of death worldwide. The tissue damage in COPD is severe and irreversible. Therefore, there is an urgent need for regenerative cell therapy for tissue restoration in COPD.
Within the UMCG, the PhD student will work with the ex vivo lung perfusion model where the main focus will be optimization of the model for administration of regenerative therapies developed within the RecovAir consortium. The ex vivo lung perfusion will be performed in cadaveric animal lungs and human explanted COPD lungs. In addition, further studies will be performed on deposition/distribution and engraftment of regenerative cells after the initial optimization.
The PhD student will be working within the department of Pulmonary Diseases and Tuberculosis of the UMCG. The research will be embedded within the Groningen Research Institute for Asthma and COPD (GRIAC), a multidisciplinary and highly translational research institute performing fundamental and applied patient-related research with the aim to unravel underlying mechanisms of the development and progression of lung diseases, including asthma, COPD and pulmonary fibrosis.
The project is part of a national consortium, where there will be close collaboration with the department of Cardiothoracic Surgery (dr. Erasmus) and Pathology & Medical Biology (Prof. dr. Heijink, Prof. dr. Brandsma and Prof. dr. Nawijn), and laboratory of Experimental Pulmonology and Inflammation Research (EXPIRE). Within these departments multiple renowned research groups work on pathophysiological damage and repair processes, using translational and multi-omic approaches (transcriptomics e.g. single cell RNA sequencing, proteomics etc), and state-of-the-art cellular and molecular techniques, to obtain insights into novel therapeutic strategies. In addition there will be a close collaboration with the consortium partners from University of Groningen (Prof. dr. Gosens), Twente University (Prof. dr. Leijten and Prof. dr. Prakash) and University Medical Center Leiden (Dr. van der Does, Prof dr. Hiemstra and Prof. dr. J.J. Zwaginga).
TThe UMCG has a preventive Hepatitis B policy. The UMCG can provide you with the vaccination, should it be required for your position. In case of specific professions a ‘Certificate of Good Conduct’ is required.
We offer a 4 year PhD position for 32 to 36 hours per week, with a go/no-go decision after 12 months. Your salary will be a maximum of € 3.824,- gross per month (scale PRO), depending on your qualifications and relevant experience, based on a full-time appointment. In addition, the UMCG will offer you 8% holiday pay, and 8.3% end-of-year bonus. The conditions of employment comply with the Collective Labour Agreement for Medical Centres (CAO-UMC).
Het Universitair Medisch Centrum Groningen (UMCG) is één van de grootste ziekenhuizen in Nederland en is de grootste werkgever van Noord-Nederland. De ruim 12.000 medewerkers werken samen aan zorg, onderzoek, opleiding en onderwijs met als gemeenschappelijke doelstelling: bouwen aan de toekomst van gezondheid.
Deze bedrijfspagina is automatisch gegenereerd en bevat daarom nog weinig informatie. Je vindt meer informatie over ‘bedrijfsnaam’ op hun website: ‘’Carrierewebsite’’
Resources:
Change language to: English
Deze pagina is geoptimaliseerd voor mensen uit Nederland. Bekijk de versie geoptimaliseerd voor mensen uit het Verenigd Koninkrijk.